BRIACELL THERAP (BCTX)
(Delayed Data from NSDQ)
$0.68 USD
+0.05 (8.49%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $0.68 0.00 (-0.51%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BCTX 0.68 +0.05(8.49%)
Will BCTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BCTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCTX
BRIACELL THERAP (BCTX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
BRIACELL THERAP (BCTX) Upgraded to Buy: What Does It Mean for the Stock?
BCTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes BRIACELL THERAP (BCTX) a New Strong Buy Stock
Other News for BCTX
BriaCell Announces Proposed Effective Date of Share Consolidation | BCTX Stock News
BriaCell (BCTX) Expands Phase 3 Breast Cancer Study with UCLA Health
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study | BCTX Stock News
BriaCell adds UCLA Health as site in Phase 3 breast cancer study
BriaCell (BCTX) Secures New Zealand Patent for Innovative Cancer Vaccine